Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to track the cost of implementing the cross-border travel measures in response to covid-19.
Answered by Maggie Throup
The Government reviewed scientific advice and evidence and lessons learned from the border response to adapt the approach and target measures where needed. The UK Health Security Agency is currently developing border contingency measures, which could be implemented should a variant of concern emerge. As part of this contingency planning, Departments are considering which data will be required to ensure the response can be monitored and adapted as required. The costs of implementing health measures at the border were considered at Departmental level and were monitored through standard budget management and governance procedures.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will introduce a set of performance measures to track the effectiveness of the specific measures deployed to manage cross border travel during the covid-19 pandemic.
Answered by Maggie Throup
The Government reviewed scientific advice and evidence and lessons learned from the border response to adapt the approach and target measures where needed. The UK Health Security Agency is currently developing border contingency measures, which could be implemented should a variant of concern emerge. As part of this contingency planning, Departments are considering which data will be required to ensure the response can be monitored and adapted as required. The costs of implementing health measures at the border were considered at Departmental level and were monitored through standard budget management and governance procedures.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the amount fraudulently claimed in refunds by people who stayed in the managed quarantine service.
Answered by Maggie Throup
An estimated £18 million has been fraudulently claimed in refunds through the Managed Quarantine Service. All appropriate debts have been passed to the Department’s debt recovery partner, Qualco, for collection.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Paymaster General of 5 January 2022, Official Report, column 122, if he will list the more than 30 British-based companies who have signed contracts to provide 3.9 billion items of PPE including information on (a) the number and percentage of PPE items provided by each company and (b) the monetary value of each contract.
Answered by Edward Argar - Minister of State (Ministry of Justice)
The Department has signed contracts with 31 United Kingdom-based companies for 3.9 billion units of personal protective equipment (PPE), of which 2.5 billion units have been delivered so far. Currently, 247 million items are yet to be manufactured, although these orders are scheduled to be delivered by the end of March 2022. The 3.9 billion items represent 10.7% of all items ordered during the pandemic.
The following table shows the companies involved in the UK Make programme. Contracts have been signed with two further UK-based companies. However, as some items are not manufactured in the UK, these products are not included in the 3.9 billion total.
Supplier | Number of items | Total value | Percentage of all UK Make items |
Alpha Solway (Globus) | 100,300,000 | £187,419,000 | 2.552% |
Blue Tree Group | 352,180,000 | £64,096,760 | 8.959% |
Bolle Brands UK | 9,751,688 | £39,006,750 | 0.248% |
Burberry | 4,000,000 | £660,000 | 0.102% |
Burberry | 50,000 | £573,000 | 0.001% |
Don & Low | 216,000,000 | £41,040,000 | 5.495% |
Dräger | 50,000,000 | £87,250,000 | 1.272% |
Dtr Medical Ltd | 1,300,000 | £6,500,000 | 0.033% |
Duraweld Ltd | 5,200,000 | £4,212,000 | 0.132% |
Elite Plastics | 180,000,000 | £9,900,000 | 4.579% |
Eumar Technology | 105,000,000 | £19,950,000 | 2.671% |
Honeywell | 70,285,000 | £57,939,250 | 1.788% |
I Love Cosmetics (Expac) | 6,971,328 | £15,964,341 | 0.177% |
Kingsbury Press | 13,000,000 | £12,870,000 | 0.331% |
L J A Miers And Company Ltd | 13,000,000 | £14,950,000 | 0.331% |
Lincoln Polythene | 1,038,250,000 | £46,721,250 | 26.412% |
McDonald & Taylor | 1,155,354 | £5,661,235 | 0.029% |
Medicom | 540,000,000 | £86,400,000 | 13.737% |
Medicom | 122,900,000 | £221,220,000 | 3.126% |
Numatic International Ltd | 390,000 | £975,000 | 0.010% |
PFF Packaging | 360,023,000 | £18,361,173 | 9.159% |
Photocentric Ltd | 7,670,000 | £15,340,000 | 0.195% |
Polystar Plastics | 553,400,000 | £32,037,228 | 14.078% |
Potter & Moore | 4,950,000 | £8,167,500 | 0.126% |
Private White | 15,300,000 | £2,448,000 | 0.389% |
Private White | 1,080,070 | £7,120,921 | 0.027% |
Ramfoam Limited | 71,100,000 | £149,310,000 | 1.809% |
Redwood | 379,460 | £2,078,682 | 0.010% |
Siva Plastics | 60,000,000 | £6,400,000 | 1.526% |
Staeger Clear Packaging Ltd | 24,000,000 | £14,640,000 | 0.611% |
Survitec | 1,920,000 | £30,541,509 | 0.049% |
The Royal Mint Ltd | 1,404,000 | £8,424,000 | 0.036% |
Total | 3,930,959,900 | £1,218,177,598 | 100% |
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will provide the (a) number and (b) proportion of PPE items provided by each company identified through the High Priority Lane; and what the monetary value of each of those contracts was.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We are unable to provide the information requested on the number and proportion of personal protective equipment (PPE) items provided by each company identified through the High Priority Lane, as it is commercially sensitive. The following table shows the monetary value for each contract for PPE processed through the high priority lane.
Supplier | Contract value |
Aiya Technology | £2,790,000.00 |
Aiya Technology | £14,600,000.00 |
Aiya Technology | £6,240,000.00 |
Aventis Solutions Ltd | £18,480,000.00 |
Ayanda Capital Ltd | £252,500,000.00 |
Blueleaf Ltd | £4,000,000.00 |
Brandology Ltd | £29,315,000.00 |
Brandology Ltd | £69,600,000.00 |
Cargo Services Far East Limited | £49,209,350.40 |
Cargo Services Far East Limited | £107,273,180.91 |
Cargo Services Far East Limited | £1,802,805.61 |
Ccs Mclays Ltd | £11,136,000.00 |
Community Pharma Company Ltd | £3,920,000.00 |
Crisp Websites Ltd Ta Pestfix | £32,436,000.00 |
Crisp Websites Ltd Ta Pestfix | £1,104,000.00 |
Crisp Websites Ltd Ta Pestfix | £30,000,000.00 |
Crisp Websites Ltd Ta Pestfix | £71,750,000.00 |
Crisp Websites Ltd Ta Pestfix | £1,628,700.00 |
Crisp Websites Ltd Ta Pestfix | £6,755,000.00 |
Crisp Websites Ltd Ta Pestfix | £139,900,000.00 |
Crisp Websites Ltd Ta Pestfix | £197,800.00 |
Crisp Websites Ltd Ta Pestfix | £454,500.00 |
Crisp Websites Ltd Ta Pestfix | £490,500.00 |
Euthenia Investments Ltd | £880,000.00 |
Excalibur Healthcare Services Ltd | £25,135,000.00 |
Eyespace Eyewear Limited | £1,412,829.18 |
Gbuk Ltd | £2,360,484.00 |
Global United Trading | £432,719.25 |
Headwind Industrial (China) Ltd | £2,500,000.00 |
Hotel Logistics Ltd | £3,667,957.14 |
Hotel Logistics Ltd | £1,025,000.00 |
Hotel Logistics Ltd | £615,000.00 |
Ideal Medical Solutions Ltd | £7,500,000.00 |
Ideal Medical Solutions Ltd | £7,500,000.00 |
Ideal Medical Solutions Ltd | £14,955,000.00 |
Ideal Medical Solutions Ltd | £6,090,000.00 |
Ideal Medical Solutions Ltd | £3,940,000.00 |
Invisio Ltd | £3,789,500.00 |
Invisio Ltd | £8,500,000.00 |
Jingdong E-Commerce | £8,497,272.65 |
Jingdong E-Commerce | £8,424,570.18 |
Kpm Marine Ltd | £960,000.00 |
Liaoning Zhongqiao Overseas Exchange Co., Ltd. | £12,779,067.68 |
Maxima Markets Limited | £1,850,000.00 |
Mayfair Global Uk Ltd | £256,000.00 |
Mds Healthcare Ltd | £150,000.00 |
Mds Healthcare Ltd | £2,350,000.00 |
Medicom Healthcare Holding | £307,620,000.00 |
Medicom Healthcare Holding | £299,906,668.00 |
Meller Design Ltd | £8,647,462.14 |
Meller Design Ltd | £1,080,000.00 |
Meller Design Ltd | £65,832,000.00 |
Meller Design Ltd | £2,610,000.00 |
Meller Design Ltd | £79,170,000.00 |
Meller Design Ltd | £5,990,601.73 |
Mgp Advisory Ltd | £825,000.00 |
Monarch Acoustics Ltd | £28,800,000.00 |
New Asia Logistic Services Pte Ltd | £17,010,000.00 |
Nine United Ltd | £48,545,750.30 |
Nine United Ltd | £13,937,752.96 |
Nkd International Limited | £135,000.00 |
P14 Medical Ltd Ta Platform 14 | £4,192,812.00 |
P14 Medical Ltd Ta Platform 14 | £116,013,156.00 |
P14 Medical Ltd Ta Platform 14 | £156,291,000.00 |
P1f Limited | £738,805.98 |
P1f Limited | £7,590,000.00 |
P1f Limited | £4,020,500.00 |
P1f Limited | £7,300,000.00 |
P1f Limited | £259,000.00 |
P1f Limited | £36,116,578.62 |
P1f Limited | £25,600,000.00 |
P1f Limited | £2,413,800.00 |
Pakan Health And Beauty Group | £1,944,000.00 |
Ppe Medpro Ltd | £80,850,000.00 |
Ppe Medpro Ltd | £122,000,000.00 |
Regal Polythene Ltd Ta Regal Disposables | £44,400.00 |
Regal Polythene Ltd Ta Regal Disposables | £1,125,000.00 |
Rehear Labs Limited | £9,750,958.96 |
Rehear Labs Limited | £13,400,000.00 |
Rehear Labs Limited | £30,740,000.00 |
Sanaclis | £11,000,000.00 |
Sanaclis | £6,000,000.00 |
Sg Recruitment Uk Ltd | £23,899,000.00 |
Sg Recruitment Uk Ltd | £16,125,000.00 |
Skinnydip Limited | £12,873,400.00 |
Summit Medical Ltd | £161,058.40 |
Technicare Ltd Ta Blyth Group | £1,725,000.00 |
The Paper Drinking Straw Company Ltd | £19,877,000.00 |
Tower Supplies | £20,250,000.00 |
Tower Supplies | £20,250,000.00 |
Uniserve Ltd | £10,000,000.00 |
Uniserve Ltd | £69,600,000.00 |
Uniserve Ltd | £13,500,000.00 |
Uniserve Ltd | £7,125,000.00 |
Uniserve Ltd | £14,400,000.00 |
Uniserve Ltd | £287,960,000.00 |
Uniserve Ltd | £86,200,000.00 |
Unispace Global Health | £239,600,000.00 |
Unispace Global Health | £113,950,000.00 |
Unispace Global Health | £103,684,000.00 |
Unispace Global Health | £161,000,000.00 |
Unispace Global Health | £47,846,500.00 |
Unispace Global Health | £3,789,590.00 |
Unispace Global Health | £9,660,000.00 |
Universal Solutions Trading Ltd | £810,000.00 |
Universal Solutions Trading Ltd | £2,700,000.00 |
Universal Solutions Trading Ltd | £4,500,000.00 |
Urathon Europe Limited | £52,480,000.00 |
Urathon Europe Limited | £22,200,000.00 |
Visage Ltd | £3,375,000.00 |
Visage Ltd | £3,000,000.00 |
Worldlink Resource | £80,100,000.00 |
Worldlink Resource | £178,200,000.00 |
Wuhan Xiaoyaoyao Pharmaceutical | £63,339,414.97 |
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the (a) number and (b) proportion is of people who received PCR test results within (i) 24 hours, (ii) 48 hours, (iii) 72 hours and (iv) 96 hours or more.
Answered by Maggie Throup
This information is not held in the format requested and could only be obtained at disproportionate cost.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to Ministerial Statement HC WS324 made on 18 October 2021, whether his Department has plans for the continued supply and usage of tests on the Coronavirus Test Device Approvals (CTDA) exempt list after the 28 February 2022 deadline in the event the approval process is not completed on schedule.
Answered by Maggie Throup
There was no requirement for Coronavirus Test Device Approvals (CDTA) reviews to be completed by 28 February 2022. This date refers to a temporary protocol which applied from 1 November 2021 to 28 February 2022, which allowed tests to stay on the market pending their CTDA outcome.
A new protocol containing two lists took effect from 1 March 2022, one for three months for certain devices until 31 May 2022 and one for six months until 31 August 2022, which is available at the following link:
The new protocol allows the continued supply and procurement of those tests, whilst their CTDA application is being considered.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans the Government has to improve the transparency of the Coronavirus Test Device Approval process.
Answered by Maggie Throup
The Government is satisfied with the level of transparency throughout the Coronavirus Test Device Approval process.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the reliance and expenditure on consultants in providing NHS Track and Trace.
Answered by Maggie Throup
The UK Health Security Agency produced a workforce strategy in July 2021 detailing plans to reduce the use of consultancy services and increase the proportion of civil servants employed by the organisation. Reducing the number of management consultants is balanced with the delivery of national priorities, ensuring the sustainable handover of critical knowledge and managing recruitment into highly skilled roles. In 2021/22, reductions in the number of consultants has produced a saving of £100 million.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 February 2022 to Question 119864, what the evidential basis is for the statement that (a) approval of covid-19 tests for private use falls under the Coronavirus Test Devices Approvals regulation (CTDA) and (b) only devices that meet the high regulatory standards are available to the British public, in the context of known Chinese-manufactured tests that have not been assessed under the CTDA process.
Answered by Maggie Throup
The Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (CTDA) provides a regulatory framework for manufacturers and their representatives seeking to sell COVID-19 tests in-scope of the legislation on the private market or supply tests to private sector testing services in the United Kingdom. It establishes standards to protect consumers and enable high quality tests to enter the market, regardless of the country of origin.
A test must either be approved under the CTDA or be included in a protocol that lists tests that are allowed to remain on the market while their CTDA application is being processed. Tests on the protocol list have received a form of verification, evaluation or validation elsewhere in the public sector, therefore their performance expected to be sufficient to protect public health. The protocol is a temporary measure and long-term access to the UK market is achieved only via CTDA approval.